发明授权
US07816405B2 Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
失效
[（2S）-3- [3 - [（2S）-3-（4-氯-2-氰基苯氧基）-2-氟丙氧基]苯基] -2-异丙氧基丙酸钙]及其中间体
![Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof](/docs/US/2010-10-19/US07816405B2/abs.jpg.600x600.jpg)
- 专利标题： Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
- 专利标题（中）： [（2S）-3- [3 - [（2S）-3-（4-氯-2-氰基苯氧基）-2-氟丙氧基]苯基] -2-异丙氧基丙酸钙]及其中间体
-
申请号： US11405619申请日： 2006-04-18
-
公开(公告)号： US07816405B2公开(公告)日： 2010-10-19
- 发明人: Masanobu Shinoda , Fumiyoshi Matsuura , Kaoru Murata , Masaharu Gotoda , Kenji Hayashi , Manabu Sasho , Naoki Ozeki , Susumu Inoue , Katsutoshi Nishiura , Yoshihiko Hisatake , Teiji Takigawa , Mamoru Miyazawa , Shigeto Negi , Keisuke Matsuyama
- 申请人： Masanobu Shinoda , Fumiyoshi Matsuura , Kaoru Murata , Masaharu Gotoda , Kenji Hayashi , Manabu Sasho , Naoki Ozeki , Susumu Inoue , Katsutoshi Nishiura , Yoshihiko Hisatake , Teiji Takigawa , Mamoru Miyazawa , Shigeto Negi , Keisuke Matsuyama
- 申请人地址： JP Tokyo
- 专利权人： Eisai R&D Management Co., Ltd.
- 当前专利权人： Eisai R&D Management Co., Ltd.
- 当前专利权人地址： JP Tokyo
- 代理机构： Birch, Stewart, Kolasch & Birch, LLP
- 主分类号： A61K31/277
- IPC分类号： A61K31/277 ; C07C255/55
![Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof](/abs-image/US/2010/10/19/US07816405B2/abs.jpg.150x150.jpg)
摘要：
The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy) -2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof.There is need for (2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same.Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S) -3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem.
公开/授权文献
信息查询
